Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca ‘on track’ after third quarter performance

AstraZeneca ‘on track’ after third quarter performance

28th October 2010

AstraZeneca has stated its confidence that it will be able to meet its financial targets for 2010 after noting several positive trends during the third quarter.

According to data from the company's new fiscal report, revenue for the quarter came to just under $7.9 billion (five billion pounds), with strong sales noted for drugs such as Symbicort, Seroquel XR and Crestor.

The company experienced a seven percent year-on-year growth in its revenue total for its operations outside the US, due primarily to its expansion in emerging markets, while figures for the first nine months of 2010 are tracking two percent ahead of 2009 levels.

AstraZeneca explained that these positive developments helped to offset trends such as an absence of pandemic influenza vaccine revenue in the US, while also noting numerous encouraging pipeline developments.

David Brennan, chief executive officer at AstraZeneca, said: "We remain firmly on track to achieve our full-year financial targets."

Earlier this week, the company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion on Fluenz, its new nasal spray vaccine for seasonal influenza.ADNFCR-8000103-ID-800199015-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.